Vorinostat is primarily used for the treatment of cutaneous T-cell lymphoma (CTCL), particularly in patients who have progressive, persistent, or recurrent disease after other therapies. Research is ongoing to evaluate its efficacy in other types of cancer, including non-Hodgkin lymphoma, multiple myeloma, and various solid tumors such as breast cancer and lung cancer.